Evestia Clinical has announced the acquisition of ICRC-Weyer GmbH, a well-established contract research organisation and scientific consultancy based in Berlin. This move strengthens Evestia Clinical’s full-service clinical research capabilities by bringing specialist expertise in biostatistics, data management and medical writing into its global offering. The deal also reinforces the company’s presence in Germany and across Europe, providing biotech innovators with more integrated support throughout clinical development. ICRC-Weyer will continue to operate under its own brand with existing services and teams remaining intact. Leadership from ICRC-Weyer, including Managing Director Johann Daniel Weyer, will join the Evestia Clinical leadership team.

The acquisition builds on Evestia Clinical’s strategy of scaling its global reach and expertise to meet the growing complexity of clinical trials, particularly in areas such as oncology, neurology and rare diseases. The expanded capabilities aim to give clients more seamless and comprehensive support as regulatory expectations evolve and trial demands increase. Evestia Clinical continues to pursue growth through targeted strategic investments as part of its ambition to be a trusted partner for biotech companies worldwide.